Key points from article :
Insilico Medicine, Juvenescence and Buck Institute have formed a new joint venture to extend life spans.
The combined Napa Therapeutics will focus on developing NAD+ metabolism research.
“This is a unique opportunity to use cutting-edge AI to accelerate drug discovery” - Eric Verdin, CEO of the Buck Institute.
Insilico’s drug development engine is used to discover new compounds.
Juvenescence in-licenses aging-related assets.
“The Buck is excited to join with Insilico and Juvenescence as we work to eliminate the threat of age-related disease" - Verdin.
Verdin’s lab is studying the role of sirtuins, deacylating enzymes and signaling metabolites from the mitochondria, and their regulation of aging.
“Aging research will improve and extend the lives of everyone on the planet and reduce the pain and suffering associated with the age-associated diseases” - Alex Zhavoronkov, CEO of Insilico Medicine.
